Janux Therapeutics Inc
JANXHealthcare|Biotechnology|USA
$16.41
-0.35 (-2.09%)
DCF (FCF)
$5.59
Tangible Book
$15.47
About
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Stock Price
-35.9%(1Y)
Pipeline Summary
4 total trials3
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 3Active: 1
Active Trials (4)
Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
NCT07291323Autoimmune
Early P1Recruiting
Enrollment: 60 participants
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05783622Non-Small Cell Lung Cancer
Phase 1Active
Enrollment: 130 participants
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT07545811Prostate Cancer
Phase 1Recruiting
Enrollment: 43 participants
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NCT05519449Prostate Cancer
Phase 1Recruiting
Enrollment: 272 participants
BioScore
4/10
Cautious
Ownership
Recent Insider Trades
Doyle Janeen NoelSELL
2026-06-024,059 shares @ $14.03
Dobek MariaSELL
2026-05-112,038 shares @ $14.17
Meyer Andrew HollmanSELL
2026-01-021,879 shares @ $13.73
DiRaimondo ThomasSELL
2026-01-022,505 shares @ $13.73
Campbell David AlanSELL
2026-01-028,072 shares @ $13.73
Recent News
2026-06-25 14:41:34
2026-06-23 20:27:47
Data last updated: Jul 12, 2026, 07:41 PM